These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16270125)

  • 1. HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.
    Tupinambás U; Aleixo A; Greco D
    Braz J Infect Dis; 2005 Aug; 9(4):324-9. PubMed ID: 16270125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
    Clotet B; Ruiz L; Martinez-Picado J; Negredo E; Hill A; Popescu M
    HIV Clin Trials; 2002; 3(4):316-23. PubMed ID: 12187506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
    Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
    HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
    AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
    Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
    Manfredi R; Calza L
    Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
    Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
    Fitzgibbon JE; Gaur S; Walsman SM; Janahi M; Whitley-Williams P; John JF
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1321-8. PubMed ID: 11602042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
    Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nelfinavir: a review of its use in the management of HIV infection.
    Perry CM; Frampton JE; McCormack PL; Siddiqui MA; Cvetković RS
    Drugs; 2005; 65(15):2209-44. PubMed ID: 16225378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.
    Santos AF; Soares MA
    Mem Inst Oswaldo Cruz; 2011 Mar; 106(2):177-81. PubMed ID: 21537677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelfinavir: an update on its use in HIV infection.
    Bardsley-Elliot A; Plosker GL
    Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
    Markowitz M; Conant M; Hurley A; Schluger R; Duran M; Peterkin J; Chapman S; Patick A; Hendricks A; Yuen GJ; Hoskins W; Clendeninn N; Ho DD
    J Infect Dis; 1998 Jun; 177(6):1533-40. PubMed ID: 9607830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.